

Press Release

Nicox Announces a New Governance Structure

- **New governance structure with a separation of the functions of Chief Executive Officer and Chairman of the Board**
- **Andreas Segerros to be appointed as Chief Executive Officer of Nicox as of June 1st, 2022**
- **Jean-Francois Labbé, current Board member of Nicox, to become the future Chairman of the Board**
- **Co-Founder Michele Garufi will remain as a Board member of Nicox**

May 16, 2022 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its Board of Directors appointed Andreas Segerros as Chief Executive Officer of Nicox S.A on May 13th, 2022, effective from June 1st, 2022, following the Board's decision to end the mandate of Michele Garufi, who has been Chairman, Chief Executive Officer and Co-Founder of the Company since its creation in 1996. Michele Garufi will remain as Board member of Nicox SA.

The Board has also decided to separate the roles of Chief Executive Officer and Chairman of the Board. Current Board member and Chairman of the Audit Committee, Jean-Francois Labbé has been proposed by the Board to become the future Chairman of the Board. This nomination is subject to the approval of an amendment to the Company's by-laws to increase the age limit for the Chairman of the Board, which will be the subject of a resolution to be voted at the Company's next Extraordinary General Meeting. During the interim period, the Board of Directors has nominated Michele Garufi as interim Chairman of the Board, effective from June 1st, 2022.

Michele Garufi, Chairman of the Board of Nicox SA said *"Having led Nicox from its foundation to becoming one of the most promising European Ophthalmic R&D Companies, I am pleased that the Board has decided to hand over the leadership of the company to Andreas Segerros. I am very confident that Andreas and the team will continue to successfully develop Nicox as a major player in the ophthalmic field through the last phase of development of NCX 470. I will be honored to support Andreas as a Board member and I wish him all the best in his new endeavor. At the same time, I would like to heartily thank all of my collaborators, the Board members and all of our business partners during the years of my Presidency who have largely contributed in making Nicox a leader in its therapeutic field."*

"Working to bring novel and innovative ophthalmic treatments to market has been an important part of my professional life, and renewing that commitment with Nicox is indeed an honor," said **Andreas Segerros, Chief Executive Officer of Nicox SA**. *"With its rich pipeline, near term development of NCX470, and the hard work and vision of a talented and passionate team, we can look forward to delivering products to treat some of the world's most prevalent and serious ophthalmic disorders, with the potential to make a meaningful difference in the lives of patients."*

Andreas Segerros

Andreas Segerros has spent most of his career in global pharma, with executive positions (R&D, Marketing and Business Development) in the U.S., Europe and Japan, at Pharmacia, Pharmacia & Upjohn and Ferring, with the focus on specialty Pharma, ophthalmology in particular. As Global Head of Ophthalmology at Pharmacia, Andreas launched XALATAN® (latanoprost), making it the industry's first billion-dollar ophthalmic drug. His venture capital experience comes from being Partner at the Scandinavian group Sunstone Capital, and also co-founded Eir Ventures. Andreas has made numerous

investments in successful companies in Europe and the U.S. Andreas holds an MSc in Organic Chemistry from The Royal Institute of Technology in Stockholm, Sweden, and an MBA in International Financing from The University of Uppsala, Sweden.

Jean-Francois Labbé

Jean-François Labbé has served as a member of Nicox' Board of Directors since 2010 and has been the Chairman of the Audit Committee of Nicox since 2013. M. Labbé is the Founder and Chief Executive Officer of SpePharm Holding BV, a pan-European specialty pharma company. Prior to founding SpePharm, M. Labbé served as Chief Executive Officer of OTL Pharma SA from 2001 to 2004 and as Chief Operating Officer of ProStrakan UK from 2004 to 2005. He began his career at Roussel Uclaf in 1974, then Hoechst Roussel and HMR, where he served in various positions in Europe, the United States and was a member of the HMR's Executive Committee before its merger with Aventis in 1999. M. Labbé received an MBA from the Ecole des Hautes Études Commerciales (HEC), Paris, France.

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for dry eye disease. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIAE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment C: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co	Dylan van Haaften	Paris, France
Edison Investment Research	Pooya Hemami	London, UK
H.C. Wainwright & Co	Yi Chen	New York, U.S.
Kepler Cheuvreux	Arsene Guekam	Paris, France



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts

Nicox

Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investors & Media

United States & Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
svonderweid@lifesciadvisors.com

Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox SA and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox SA and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 3rd chapter of the 'Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2021' filed with the French Autorité des Marchés Financiers (AMF) on April 29, 2022 which is available on Nicox's website (www.nicox.com).



Nicox SA

Drakkar 2

Bât D, 2405 route des Dolines

CS 10313, Sophia Antipolis

06560 Valbonne, France

T +33 (0)4 97 24 53 00

F +33 (0)4 97 24 53 99